Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferro Sanol Duodenal versus Niferex in iron deficiency anemia
2014-004380-20Phase 3
- Sponsor
- Sanol GmbH
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) comparing Ferro Sanol Duodenal with Niferex (2 arms). Primary endpoint: Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 12.
02
Drugs
ferroglycine sulfateferrous aspartoglycinate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2014-004380-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004380-20.